1.In Vitro Antibacterial Activity of Tanreqing Injection Combined with Cefuroxime Sodium Injection Against Staphylococcus Aureus
Chunsheng YAN ; Haiying XU ; Qingge CHEN ; Li WANG ; Chaoyi LIU
Herald of Medicine 2016;35(7):728-731
Objective To explore the in vitro antibacterial effect of tanreqing injection combined with cefuroxime sodium injection against staphylococcus aureus. Methods The MIC of tanreqing injection or cefuroxime sodium injection against staphylococcus aureus was detected by microamount dilution method.The antibacterial activity of tanreqing injection combined with cefuroxime sodium injection was determined by a chess board dilution method and assessed according to FIC index. Results The MIC of tanreqing injection and cefuroxime sodium injection against staphylococcus aureus was 1∶256 and 2 μg . mL-1 , respectively. While combined with each other, the MIC of tanreqing injection and cefuroxime sodium injection against staphylococcus aureus was 1∶4 096 and 0. 125 μg . mL-1 , respectively. The FIC index of tanreqing injection combined with cefuroxime sodium injection against staphylococcus aureus was 0. 125. Conclusion Tanreqing injection has a synergistic antibacterial effect against staphylococcus aureus when it was combined with cefuroxime sodium injection.
2.Construction and application of a telemedicine-based home care system of palliative care for end-of-life cancer patients
Junchen GUO ; Chaoyi LIU ; Xianghua XU ; Yunyun DAI ; Suo YANG ; Yongyi CHEN ; Yazhou XIAO
Chinese Journal of Nursing 2024;59(16):1925-1933
Objective To construct a telemedicine-based home care system of palliative care for end-of-life cancer patients,and to evaluate its application effect.Methods The construction of the system was based on the literature research,interview results of the patients and their caregivers,and expert group meeting discussions.From May to August 2023,a total of 88 patients,who were about to be discharged from the palliative care ward of a cancer hospital in Hunan Province,were selected as the study subjects using a convenient sampling method,and then they were divided into an experimental group and a control group according to the order of admission.The experimental group was given home care services based on the system,while the control group was given routine discharge guidance and follow-up visits.The duration of the intervention was 8 weeks.The Chinese version of the Edmonton Symptom Assessment Scale and the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 palliative were used to evaluate the symptom burden and quality of life between 2 groups before and after intervention;the Telemedicine Satisfaction Questionnaire was used to evaluate the care satisfaction of the experimental group.Results The system of patient side includes 8 main features,namely personal health record establishment,doctor-patient communication,palliative care knowledge library,medication assistance,smart reporting and monitoring,intelligent Q&A,intelligent follow-up,and intelligent forms.The healthcare professional side includes 7 main functions,namely workbench,case management,follow-up management,warning reminder,popularization push,statistical analysis and user management.A total of 67 patients completed the intervention,with 33 in the experimental group and 34 in the control group.The symptom burden of the experimental group was lower than that of the control group(P<0.05);the quality of life in the experimental group was better than that in the control group(P<0.05);the score of care satisfaction was(59.00±6.66),which indicated a high level of satisfaction.Conclusion The system can reduce the symptom burden and improve the quality of life of end-of-life cancer patients with good practicality
3.Literature Study on Pharmacoeconomic Evaluation of Aspirin for Cardiovascular Disease Prevention
Gangpeng ZHONG ; Wei XU ; Chaoyi LIU ; Haijiao LIU ; Tianyu JING ; Xiaoqing HUANG
China Pharmacy 2021;32(16):2002-2007
OBJECTIVE:To review the method and results of pharmacoeconomic evaluation of aspirin for cardiovascular disease prevention ,and to provide reference for economic evaluation of aspirin and clinical medication decision. METHODS : Using“cardiovascular disease ”“cost-effectiveness”“cost-utility”“cost-benefit”“cost effectiveness ”“cost utility ”as the Chinese search terms ,using“cost-effectiveness”“cost-utility”“cost-benefit”“economic analysis ”“pharmacoeconomics”as English search terms,relevant literatures about pharmacoeconomic evaluation of aspirin for cardiovascular disease prevention published during January 1,2000 to January 17,2021 were retrieved from CNKI ,Wanfang database ,VIP,PubMed,Web of Science ,the Cochrane Library. After screening literatures according to inclusion and exclusion criteria ,extracting relevant data ,the quality of included literatures was evaluated with CHEERS scale. The method and results of pharmacoeconomic evaluation of aspirin in the prevention of cardiovascular diseases were analyzed statistically in terms of basic information ,literature quality ,model structure and elements ,health status and utility value ,cost items and sources ,health output ,economic evaluation and sensitivity analysis. RESULTS & CONCLUSIONS :Nine literatures were included ,and the total coincidence rates of the literatures were all above 80.00%. The pharmacoeconomic evaluation of aspirin in the prevention of cardiovascular disease mainly adopted Markov model , and the model structure was relatively mature. The cost mainly considered the direct cost ,and the data mainly came from the medical insurance database ;utility was calculated according to the utility value of health state ,which mostly came from the existing literatures. The sensitivity analysis adopted deterministic sensitivity analysis and probabilistic sensitivity analysis ,and the main influential factor was cost. It was economical to use aspirin for cardiovascular disease prevention in most cases ,and aspirin was more economical for primary prevention of cardiovascular disease. It is suggested that domestic scholars can refer to China ’s pharmacoeconomic guidelines to carry out relvant pharmacoeconomic evaluation research more standardized.
4.Efficacy,safety and cost-effectiveness of polyisobutylene-type Gutong plaster in the treatment of osteoarthritis in Chinese adults
Tianyu JING ; Chaoyi LIU ; Haijiao LIU ; Gangpeng ZHONG ; Xiaoqing HUANG ; Wei XU
China Pharmacy 2023;34(12):1478-1482
OBJECTIVE To evaluate the efficacy, safety and cost-effectiveness of polyisobutylene (PIB)-type Gutong plaster (called “PIB Gutong plaster” for short) versus non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis in Chinese adults. METHODS Based on a real-world study, after propensity score matching, the decrease in pain visual simulation score, utility increase, time to pain resolution, time to return to normal range of motion and total adverse events of PIB Gutong plaster versus three NSAIDs (celecoxib, diclofenac sodium, and ibuprofen) were evaluated. Cost-utility analysis was used to calculate the incremental cost-effectiveness ratio (ICER) of patients using PIB Gutong plaster versus the three NSAIDs from the perspective of the whole society, and sensitivity analysis was carried out. RESULTS In terms of effectiveness, the recovery time of joint activity in PIB Gutong plaster group was significantly longer than that in celecoxib group, the decrease in VAS score of PIB Gutong plaster was significantly higher than that of ibuprofen but significantly lower than that of diclofenac sodium; the time of pain disappearance was longer than that in diclofenac sodium group and ibuprofen group, and the increase in health utility was significantly lower than that in diclofenac sodium group (P<0.05). In terms of safety, there were no significant differences in the incidence and severity of adverse events of PIB Gutong plaster, compared with the three NSAIDs, without statistical significance (P<0.05). In terms of cost-effectiveness, compared with celecoxib and diclofenac sodium, PIB Gutong plaster was dominant. Compared with ibuprofen, the ICER value of PIB Gutong plaster was 178 611.58 yuan/QALY, indicating that at the current price, PIB Gutong plaster was cost-effective if the threshold was 3 times GDP per capita. The results of sensitivity analysis were consistent with those of basic analysis. CONCLUSIONS The efficacy of PIB Gutong plaster was better than that of ibuprofen, similar to that of celecoxib, but worse than that of diclofenac sodium, the safety was consistent with the three NSAIDs, and the cost-effectiveness of PIB Gutong plaster needs to be improved.
5.Progress in regulatory mechanism for inducing β-lactamase in Gram-negative bacteria.
Chaoyi XU ; Ting ZHANG ; Jingxiao CAI ; Zhiliang YU ; Juanping QIU ; Jianhua YIN
Chinese Journal of Biotechnology 2018;34(8):1288-1296
Beta-lactams are the most widely used antibiotics. One of the principle mechanisms for Gram-negative bacteria to resist β-lactams is by producing β-lactamases that degrade β-lactams. This review highlights two regulatory mechanisms for inducing β-lactamase in Gram-negative bacteria. In the ampR-ampC paradigm, the induction of β-lactamase is intimately linked to peptidoglycan recycling. AmpR, a LysR-type transcriptional regulator, plays a central role in regulating expression of β-lactamase. Recent studies found that two-component signal transduction pathway is activated by β-lactams, which in turn induces the expression of β-lactamase. Finally, we discussed the future research directions in β-lactam resistance in Gram-negative bacteria.
6.Analysis Study of Pharmacoeconomic Evaluation Model of Therapy for Type 2 Diabetes Mellitus
Haijiao LIU ; Yajie WANG ; Yuxia WU ; Chaoyi LIU ; Xitao LIU ; Wei XU
China Pharmacy 2020;31(19):2392-2398
OBJECTIVE:To analyze th e general characteristics and application of the models used in the pharmacoeconomic evaluation of type 2 diabetes mellitus (T2DM)therapy during the past 5 years,and to provide reference for the selection and improvement of T 2DM pharmacoeconomic model. METHODS :Retrieved from PubMed ,Embase,CNKI,Wanfang database and VIP during Jan. 1st,2015 to Dec. 31st,2019,pharmacoeconomic evaluation literatures about T 2DM therapy were collected ;the included model was analyzed in respects of general structure ,therapy plan establishment , short-term therapeutic efficacy , complication simulation ,model effectiveness validation ,application frequency. RESULTS :A total of 81 literatures were included , involving 14 models,such as CORE model ,Cardiff model ,ECHO model ,etc. Mostly ,Markov or micro Markov simulation method were adopted to measure the patient ’s lifetime health outcome and cost mostly from the point of view of third-party payer. Seven models could simulate 2-4 therapy plans ;short-term efficacy mainly included risk factors of diabetic complications (such as glycosylated hemoglobin level and body mass )and adverse drug reactions. Most models used intermediate indexes to simulate the occurrence of complications ,and the number of complications ranged from 3 to 15;the validity of model effectiveness included surface validity ,internal validity and external validity ,etc. Among 14 models,the most frequently used models in the past 5 years were long-term models that had been validated ,among which CORE model had the most application times (38/81,46.91%), followed by Cardiff model (12/81,14.81%). CONCLUSIONS :The 14 models have similar structure. The differences of the models are mainly reflected in 3 aspects as therapy plan setting, considered short-term efficacy , the number of model are ideally choose based on available evidences.